Navigation Links
HCA Reports Second Quarter 2008 Results
Date:7/31/2008

p> Net cash provided by (used in) financing

activities 200 (268)

Change in cash and cash equivalents (25) (280)

Cash and cash equivalents at beginning of period 393 634

Cash and cash equivalents at end of period $368 $354

Interest payments $1,007 $1,092

Income tax payments, net of refunds $532 $227

HCA Inc.

Operating Statistics

For the Six Months

Second Quarter Ended June 30,

2008 2007 2008 2007

Consolidating Hospitals:

Number of Hospitals 161 164 161 164

Weighted Average Licensed

Beds 38,419 39,222 38,413 39,245

Licensed Beds at End of

Period 38,448 39,175 38,448 39,175

Reported:

Admissions 382,600 383,200 784,300 787,000

% Change -0.2% -0.4%

Equivalent Admissions 587,600 582,500 1,188,900 1,183,700

% Change 0.9% 0.4%

Revenue per Equivalent

Admission $11,878 $11,552 $11,865 $11,325

% Change 2.8% 4.8%

Inpatient Revenue per

Admission $11,175 $10,900 $11,193 $10,638

% Change 2.5% 5.2%

Patient Days 1,887,600 1,899,500 3,912,200 3,921,000

Equivalent Patient

Days
'/>"/>

SOURCE HCA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...nter (URMC) has received a U.S. patent for a diagn...creen for organisms such as bacteria and other inf...hester-based life sciences company, is the exclusi... The company,s technology platform called NanoLa...quences from biological samples, a process that ca...
(Date:1/8/2009)...e-FirstCall/ -- Warner Chilcott Limited (Nasdaq: ...e 27th Annual JP Morgan Conference on Tuesday, Jan...ner Chilcott will be Roger Boissonneault, Presiden...Executive Vice President and Chief Financial Offic...webcast live for all interested parties at www.wc...
(Date:1/8/2009)...-- Most people are used to the clutter in their ho...piles of trash block hallways, the top of the bed ...ometimes never found) in the chaos, the disorganiz...eaceful life and could be taking its toll on your ...ions: Vibrant Health, Balanced Living magazine,s ...
(Date:1/8/2009)...ira Pharmaceuticals, a small molecule pharmaceutic...lopment of compounds to treat inflammatory disease...erson, Professor Jerold Chun and Professor Andrew ...er strengthens the Board that includes Professor F...tory diseases, Harvard Medical School ), Professo...
Breaking Medicine News(10 mins):Health News:URMC, Lighthouse Biosciences awarded US patent for diagnostic technology 2Health News:Is Clutter Making You Fat? Take Natural Solutions Magazine's Clutter Quiz and Get Home Organizing Tips for 2009 2Health News:Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager 2Health News:Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager 3
...uman bird flu samples, the World Health Organisati...eluctance //to send the samples could frustrate gl... human samples of the H5N1 virus with WHO collabor... has since reported five more human infections and...
...me out with research findings they hope will aid i... bits of memories //before they all fade off. Say...biology and psychiatry at UCLA's David Geffen Scho...n mice: “Making a memory is not a conscious act. L...
...Biocon Ltd. Thursday announced a 15 percent surge ...at Rs.9.9 billion in fiscal 2006-07. // The firm... 2006-07, also increased by 86 percent at Rs.380 m...o announced increase in dividend from 50 to 60 per...
...Center in Bethesda in Maryland, USA, has launched ...e. // It is now calling upon all mothers who deliv...y series of Shaken Baby Syndrome educational brief...could result in permanent danger or even death to ...
Other Medicine News:Health News:China Agrees to Share Bird Flu Samples 2Health News:Counseling to Mothers Against too Much Shaking of Children 2
(Date:1/7/2009)...an. 7 Eli Lilly and Comp...ed a complete response letter from,the U.S. Food ...acting,injection (LAI) for acute and maintenance ...ntinuing to work with the agency on the new drug,...re any additional clinical trials for the continue...
(Date:1/7/2009).... 7 ImQuest Life Sciences announce...ation to the Food and Drug Administration to initi...edione HIV inhibitor IQP-0410. ImQuest anticipates...rter of 2009. IQP-0410 is a novel small molecule i...oside reverse transcriptase inhibitor (NNRTI). The...
(Date:1/7/2009)..., January 7 Circassia Ltd, a speci... and critical care, today,announced that followin...h,its ToleroMune(R) anti-allergy technology, the ... a further phase II clinical trial in cat allergy....uited 120 patients with confirmed,cat allergies, ...
(Date:1/6/2009)... 6 In recent controlled studies co...phis , scientists found that the patented ingredie...d only proven ingredient to increase levels of nit...od nitrate/nitrate (NOx) in human subjects. , ,... increase in blood flow to the skeletal muscles. ...
Breaking Medicine Technology:FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Clot Dissolver Doesnt Boost Survival in Cardiac Arrest Patients 32511 1Clot Dissolver Doesnt Boost Survival in Cardiac Arrest Patients 32511 2Clot Dissolver Doesnt Boost Survival in Cardiac Arrest Patients 32511 3Doctors Describe First U S Face Transplant 32509 1Doctors Describe First U S Face Transplant 32509 2Doctors Describe First U S Face Transplant 32509 3Doctors Describe First U S Face Transplant 32509 4No quick or easy technological fix for climate change researchers say 6369 1No quick or easy technological fix for climate change researchers say 6369 2No quick or easy technological fix for climate change researchers say 6369 3No quick or easy technological fix for climate change researchers say 6369 4High blood sugars impact on immune system holds clues to improving islet cell transplants 6367 1High blood sugars impact on immune system holds clues to improving islet cell transplants 6367 2High blood sugars impact on immune system holds clues to improving islet cell transplants 6367 3
...laxoSmithKline today,announced results from ongoin...astatic renal cell carcinoma (RCC), ovarian cancer...presented at the,43rd Annual Meeting of the Americ... The results observed in these trials with,pazopan...an oral, investigational angiogenesis inhibitor,ta...
...swire/ -- (SEND2PRESS,NEWSWIRE) -- Epeius Biotechn...n of a historic landmark in medical oncology and a...cer gene therapy.,The first clinical report of its... issue of the International Journal of,Oncology, V...eatures of tumor destruction observed in chemo-res...
Other Medicine Technology:GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 2GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 3GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 4GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 5GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 6GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 7News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 2News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 3
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility :
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility :
GENTAMICIN SULFATE, 1000X
Gentamicin Sulphate : Antibiotic that inhibits normal protein synthesis. USBio analysed. Autoclavable.
Medicine Products: